Sunday, 16 November 2014

Hospital Pharmaceuticals Market Overview 2014 - 2020

The global hospital pharmaceuticals market was valued at USD 26.5 billion in 2013 and is estimated to reach USD 11.6 billion by 2020 declining with a CAGR of (10.5)% from 2014 to 2020.

The report defines hospital pharmaceuticals as drugs that are exclusively administered in hospital and professional healthcare facilities that encompass both in-patient as well as out-patient departments. Hospital pharmaceuticals market which had been experiencing slumps in past three to four years due to economic slowdown, patent and exclusivity loss of various orphan and blockbuster drugs is expected to recover at a rapid pace. Over a decade there has been a considerable rise in several chronic disorders that can only be treated in hospital setting such as renal failure, canter, stroke, Alzheimer's disease and angina which is expected to boost hospital pharmaceuticals market in forthcoming years.


According to World Health Organization (WHO), coronary heart diseases across the globe accounts for over 7.5 million mortalities annually. Moreover as per an analysis by Centers for Disease Control and Prevention (CDC), each year stroke kills approximately 130,000 Americans of which about 87% of them are ischemic strokes. Approximately 5.1 million people in the United States suffered from heart failure in 2013. The aforementioned statistics clearly depict the latent potential for growth owing to substantial rise in various disease indications which in last two years accounted for major source of revenue for hospital pharmacies.

The report studies the hospital pharmaceuticals market from two perspectives: major therapeutic class and indications. Market by therapeutic class includes all major drug classes that are majorly prescribed and sold in hospital pharmacies. Market by indication is segmented into six major disorders: cardiology, oncology, nephrology and urology, neurology, pain and anti-infectives. Among the mentioned indications, oncology and cardiology are key markets share declining at a CAGR of (13.01)% and (9.38)% respectively. Decline in growth rate for both the markets is majorly attributed to increasing number of drugs losing their exclusivity during the forecast period (2014-2020). Billion dollar cardiovascular medicines that are getting off patent include Exforge HCT (amlodipine/hydrochlorothiazide/valsartan), Benicar HCT (hydrochlorothiazide and olmesartan) and VESIcare (Solifenacin Succinate) in 2014, 2016 and 2018 respectively. Furthermore various billion dollar oncology drugs which will get off patent in next 5 years comprise Gleevec (Imatinib Mesylate), Tarceva (erlotinib), Zytiga (Abiraterone Acetate) and Velcade (bortezomib).


Rise in emergency department visits and increased per capita spending of patients across the globe are some of the major drivers escalating the growth of the overall market. Emergency department visits accounted for 7.4% of the total hospital visits in the U.S. in 2011 compared to 2.3% in 2010. Healthcare Cost and Utilization Project (HCUP) statistical brief data estimated that emergency department discharges increased five times (359 patients per 1,000 people) in the U.S. in 2011 compared to 2010. A large number of new molecular entities are also anticipated to be launched during the forecast period. These primarily include therapeutic areas such as cancer, neurological disorders, infections and cardiovascular diseases. All these factors would increase the global spending on medicines. Moreover, global spending on medicines is expected to increase from USD 1 trillion in 2014 to USD 1.2 trillion by 2017. Such factors are expected to boost the market for hospital pharmaceuticals market especially in case of generic drugs.


Geographically, North America market accounted for the largest share in 2013 due to 2013 due to favorable reimbursement policies, high awareness, rising per capita income, increased spending on the healthcare and greater depth of marketing efforts by key players. Total spending on healthcare in the U.S. increased from USD 320 million in 2012 to USD 330 million in 2013 depicting an increase of per capita spending by 1%. Presence of sound intellectual property in the European Union countries and presence of high quality pharmaceutical research organizations are among the few prominent drivers. Whereas, fragmented pricing system and improper reimbursement scenario and regulatory framework for clinical trials are key restraints to the European hospital pharmaceuticals market. Asia Pacific and Rest of the World are among the fastest growing markets for hospital pharmaceuticals due to the presence of large population base, aging population suffering from chronic diseases and increasing disposable income.

Browse the full press release of Hospital Pharmaceuticals Market: http://www.transparencymarketresearch.com/pressrelease/hospital-pharmaceuticals-market.htm

Leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis.

The hospital pharmaceuticals market is segmented as follows:


Global Hospital Pharmaceuticals Market, by Major Therapeutic Class

Cardiology
Anti-Adrenergic Drugs
Calcium Channel Blockers
Diuretic Drugs
Anti-Arrhythmic Drugs

Others
Oncology
Alkylating Agents
Anti-Metabolites
Hormonal Agents
Immunomodulating Agents
Miscellaneous Drugs

Nephrology and Urology
Diuretic Agents
Anti-Hypertensive Agents
Phosphate Binders
Anticholinergic Drugs
5-Alpha Reductase Inhibitors

Neurology
Anti-Anxiety Agents
Detail2Anti-Migraine Drugs
Antidepressant Drugs
Anti-Psychotic Drugs

Pain
Anticonvulsant Drugs
Anesthetic Drugs
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Opioids
Non-Narcotics Analgesic Drugs

Infection
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Antiparasite Drugs

Global Hospital Pharmaceuticals Market, by Major Indications

Cardiology
Coronary Heart Diseases
Stroke
High Blood Pressure
Heart Failure
Others

Oncology
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Others

Nephrology and Urology
Acute Kidney Failure
Chronic Kidney Diseases
Glomerular Diseases
Diabetes
Others

Neurology
Epilepsy
Alzheimer;s Disease
Parkinson;s Disease
Multiple Sclerosis
Others

Pain
Neuropathic Pain
Fibromyalgia
Osteoarthritis
Rheumatoid Arthritis
Cancer Pain

Infection
Detail1Tuberculosis
Pneumonia
Hepatitis A
Hepatitis B
Candida Infection
Fungal Meningitis
Shigellosis
Amoebiasis
Other

Global Hospital Pharmaceuticals Market, by Geography
North America
Europe
Asia Pacific
Rest of the World (RoW)


About Us:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Sheela AK
State Tower, 90 State Street,
Suite 700, Albany NY - 12207
USA/Canada Toll Free: 866-552-3453

No comments:

Post a Comment